Directory · AU
Biotechnology in Australia
A register of firms and the professionals working at them in the Biotechnology sector based in Australia. Browse the public index, then filter or export on Kipplo.
Companies
113 on file
Ozgene
Ozgene offers the full spectrum of capabilities to design, generate, breed & phenotype your mouse models. It was not that long ago that a mouse was just a mouse but, for the team at Ozgene, a mouse represents a way to advance humanity. Started 15 years ago, today, Ozgene is one of the leading companies providing genetically customised mice for researchers around the world. With best in industry timelines using their goGermline embryos other services include knock-in, knockout, humanized and transgenic mouse models, breeding and husbandry, validation and phenotyping and Geneoz VMS. Ozgene has developed a new goGermline approach, which is a revolutionary new technology to generate knockout and knock-in mice fast and efficiently, while improving animal welfare. Ozgene is now able to complete projects in less than 6 months. Whilst, Ozgene is an Australian company, 80% of their clients are located overseas and shipments leave the Ozgene facility almost daily for laboratories, small academic institutions, research institutes, biotechnology companies and multinational pharmaceutical companies in the US, Europe, Asia, South America and New Zealand. CEO and Co-founder, Dr Frank Koentgen, and the Ozgene team have over 20 years of experience in the generation of genetically modified mice. It begins even before Ozgene was born, when Dr Koentgen generated the first knockout mouse from the C57BL/6 mouse strain in 1993. Work has been published in scientific journals such as Cell, Nature, Science, Immunity, PNAS and Nature Medicine.
51 to 200 staff
Marinova Pty Ltd
Marinova is an Australian biotechnology company dedicated to the development and production of high purity seaweed extracts for the betterment of human health. We specialise in the research, development and manufacture of fucoidan compounds – highly bioactive polysaccharides derived from select species of brown seaweed. As the global leader in fucoidan science, Marinova is the supplier of choice to world-renowned research institutions. Our reputation is built on the unrivalled quality and efficacy of our bioactive fucoidan extracts and two decades of rigorous scientific investigation. Marinova’s global research and development program welcomes collaborators that share our mindset for scientific innovation. Our highly characterised fucoidan fractions are well-suited to medical device applications and pharmaceutical research. Marinova is also home to the range of unique Maritech® organic fucoidan extracts - high purity fucoidans developed specifically for nutritional, cosmetic and animal health applications. Marinova – Pure Source, Pure Science.
11 to 50 staff
Pyc Therapeutics Asx Pyc
PYC Therapeutics (ASX: PYC) is a clinical stage biotechnology company pioneering a new generation of RNA therapeutics for genetic diseases. It works by combining two complementary platforms: RNA-based drug design and PYC’s proprietary drug delivery technology. PYC's library of naturally derived cell penetrating peptides provide its delivery platform to overcome the major challenges of RNA therapeutics - getting into the target cell. PYC believes its PPMO (Peptide conjugated Phosphorodiamidate Morpholino Oligomer) technology enables a safer and more effective RNA therapeutic to address the underlying drivers of a range of genetic diseases for which no treatment solutions exist today. The Company is leveraging its leading-edge science to develop a pipeline of novel therapies including two programs focused on inherited eye diseases and preclinical discovery efforts focused on neurodegenerative diseases. PYC’s discovery and laboratory operations are located in Australia, and the Company’s preclinical and clinical operations are based in San Fransisco California.
51 to 200 staff
Agilex Biolabs Pty Ltd
Agilex Biolabs | Australia's Leading Regulated Bioanalytical CRO Agilex Biolabs is Australia's most advanced regulated bioanalytical laboratory, serving global biotechnology and pharmaceutical companies with exceptional scientific support for preclinical and clinical trials. With a legacy spanning more than 30 years, we are recognised internationally for our precision, responsiveness, and dedication to excellence in bioanalysis. From our early foundations establishing GLP and GCP-compliant services, we have grown continuously expanding our immunoassay platforms, upgrading to high-throughput automation, and onboarding cutting-edge ultra-sensitive detection technologies for biosimilars and gene therapy trials. Today, Agilex operates an expanding national laboratory network, with sites now open in Brisbane and Sydney, offering full PK, immunogenicity, biomarker, and pharmacodynamic assessments. Agilex Biolabs offers both large and small molecule bioanalysis, including quality method development, method validation, and sample analysis services with extensive cell and gene therapy capabilities and expertise. Our world-class immunoassay and immunobiology laboratories are equipped with state-of-the-art technology, including Gyrolab xPlore, MSD Quickplex 120, and BD FACSymphony A3 and Cytek Aurora flow cytometers, as well as digital droplet quantitative real-time analysis for RNA, siRNA, and miRNA clinical trials, including vaccines and gene therapy trials. Agilex also proudly operates Australia's largest fleet of mass spectrometry instruments, with 17 mass spec machines delivering unmatched analytical capacity, throughput, and precision for both large and small molecule programmes.
51 to 200 staff
Agrf Ltd
AGRF is an Australian-owned, not for profit organisation enabling world class genomics to improve quality of life through the life sciences. Our vision is to help create a healthier, more sustainable world by enabling scientific insight through genomics. Our mission is to deliver equitable access to world class multi omics solutions that drive transformative impact across research, healthcare, the environment, and industry. We partner closely with researchers and organisations to translate discovery into impact, providing access to advanced genomics and multi omics technologies, specialist expertise, and nationally integrated infrastructure. AGRF operates a coordinated network of laboratories in Brisbane, Melbourne, Adelaide, Sydney and Perth, supporting projects across the full biological spectrum - from microbes and plants to animals and human health. AGRF is supported through national research infrastructure funding provided by the Australian Government’s National Collaborative Research Infrastructure Strategy (NCRIS), via Bioplatforms Australia, together with income from the genomics services we deliver. This investment enables us to strengthen national capability and provide broad, equitable access to advanced genomics technologies. We collaborate with universities, medical research institutes, government agencies, startups, and industry partners across bioscience, biomedicine, environmental science, and agricultural biotechnology. As an independent, trusted, not for profit organisation, we exist solely to enable excellence, collaboration, and impact in genomics, in Australia and beyond.
51 to 200 staff
Inoviq Ltd Asx Iiq
INOVIQ Ltd (ASX:IIQ) is a biotechnology company developing next-generation diagnostics and therapeutics for cancer. INOVIQ has commercialised its fast, efficient and scalable EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumours.
11 to 50 staff
Protagonist Therapeutics
Protagonist Therapeutics (Nasdaq: PTGX) is a biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. Our platform enables us to discover peptides in a de novo fashion with the desired degree of potency, specificity and selectivity, and also engineer oral stability with specific peptidomimetic and chemical modifications.
51 to 200 staff
Actinogen Medical
Actinogen Medical (ASX:ACW) is an ASX-listed biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. There is a strong association between persistent stress and the production of excess cortisol that leads to changes in the brain affecting memory, cognitive function, behaviour and neuropsychological symptoms. Actinogen’s lead compound, Xanamem, has been specifically designed to reduce production of intracellular cortisol - the stress hormone - through the inhibition of the 11β-HSD1 enzyme in the brain. The 11β-HSD1 enzyme is highly concentrated in the areas of the brain associated with cognitive impairment in early Alzheimer’s Disease (AD) and Depression, and other neurological and psychiatric diseases. Because of its ability to reach these areas of the brain and inhibit this enzyme, Xanamem is very different from other treatments for cognitive impairment. Actinogen has studied 11β-HSD1 inhibition by Xanamem in more than 300 volunteers and patients, so far finding a statistically significant improvement in working memory and attention, compared with placebo, in healthy, older volunteers in two consecutive trials and clinically significant improvements in patients with biomarker-positive mild AD. Previously, high levels of target engagement in the brain with doses as low as 5 mg daily have been demonstrated in a human PET imaging study. The Company is rapidly moving forward into its upcoming double-blind, randomized, placebo-controlled Phase 2 trials in cognitive impairment in Alzheimer’s Disease and Depression to further confirm and characterize Xanamem’s therapeutic potential. The XanaMIA Phase 2b AD trial comprises 330 patients with mild Alzheimer’s Disease and the XanaCIDD Phase 2a trial will total 160 patients with depression.
11 to 50 staff
Astral Scientific Pty Ltd
Founded in 1987, Astral Scientific Pty Ltd has grown to be a key supplier to the Life Science, Diagnostic and Pharmaceutical markets. Our extensive offering of innovative products has been carefully selected to provide you and your laboratory team a value and quality proposition that is unequalled. Our growth and success have been the result of our dedication to quality, service and value to our customers - the people who ultimately use our products in their laboratories. Your 100% satisfaction is now, as it has been from the beginning, our primary concern.
11 to 50 staff
Banksia Scientific Company
Since our humble beginnings in 1980, Banksia Scientific has been a supplier to the scientific and medical community across Australia, New Zealand and the Pacific Islands. In 2004 we relocated to larger more efficient premises in Auckland and Brisbane and in 2005 we opened up our Sydney office which enabled us to provide our customers with a far more effective service further enhancing our reputation that other suppliers aspire to. A true measure of any sales organisations success is the percentage of repeat orders received and recommendations passed on and we are proud to declare an exceptionally high level of such success in this area. We aim to please and will strive to supply you with the products that you require at a sensible price, a decent level of quality and within a suitable time frame. We look forward to working with our existing customers and partners and expanding our customer base throughout the territories and providing them with the same high level of service and friendly help that our customers have become accustomed to. We would like to thank all our previous customers for your support over the past 28 years and we look forward to an exciting future with many new ventures. Please feel free to contact any of our staff to see how we can help you come to a better result for your laboratory. Banksia Scientific’s Head Office is in Bulimba, Queensland, Australia and incorporates our Australian based sales team, accounts department, orders department (both export and local) and a warehouse where most of our supplies are shipped from. The senior management is also based here with hands-on involvement in all areas of the company. Our New Zealand office is based in Auckland and incorporates our New Zealand based sales team along with the warehouse and logistics for the National orders. All stock for our New Zealand customers is held in Auckland to allow for an overnight delivery to all areas.
11 to 50 staff
Easydna Australia
EasyDNA is an international DNA testing company that specializes in offering reliable, accurate and confidential testing services to both the private and public sector all over the world. The founders of EasyDNA have been involved in this industry for over ten years and have capitalized on this experience to develop EasyDNA into a leading DNA testing service provider. EasyDNA now operates through an international network of offices in over twenty countries. Our quality promise At EasyDNA the quality of our service is of utmost importance. We offer high quality tests through our internationally accredited laboratory that is backed by a team of highly experienced scientists. Our laboratory has in fact performed over DNA tests over the years and therefore it has the necessary experience to handle a wide range of differing cases. At EasyDNA we also offer excellent levels of customer service. We understand that ordering a DNA test can be a very sensitive and trying experience, and therefore we are constantly at hand to provide you with all the information you require and to guide you through the process on a step-by-step basis. EasyDNA has also featured in a number of TV programs, soap operas and radio interviews. Moreover, the company’s services where also requested to help solve high-brow DNA testing cases involving well-known people. To read more about this, visit our media page. An extensive portfolio of tests At EasyDNA we offer a diverse portfolio of DNA testing services to cover a wide range of cases. Whilst our most common test remains the home paternity test, we also offer extensive DNA relationship testing including twin zygosity testing, that can help determine a wide range of relationships. In addition, our experienced DNA forensic team is able to offer state-of-the-art DNA forensic services, enabling us to process a wide variety of samples ranging from hair and blood to teeth and bones.
11 to 50 staff
Immvirx
ImmVirX is an Australian company founded in 2019 with a mission to improve outcomes for patients with cancer types in which immunotherapy treatments have limited effect. The company is developing a bio-selected RNA virus to induce tumour inflammation and achieve immune cell infiltration via the RIG-I pathway. The targets for this approach are Ovarian, Head & Neck and those indications which present with liver metastases such as Colorectal, Hepatocellular carcinoma and Pancreatic cancer. The approach includes combination therapy with Immune Checkpoint Inhibitors and CAR-T agents using bio-selected RNA virus. The company founders, Malcolm McColl and Prof. Darren Shafren, were Managing Director and CSO of Viralytics, an ASX listed oncolytic virus company acquired in June 2018 by Merck and Co. Inc. for A$502 million. The ImmVirX team includes key management and researchers from Viralytics and is based at the former Viralytics laboratory facilities in Newcastle Australia.
11 to 50 staff
Mx3 Diagnostics
THE POWER OF A LAB IN THE PALM OF YOUR HAND MX3 is changing what's possible for health diagnostics. This revolutionary platform is the first simple, reliable way to measure and track salivary and sweat biomarkers anytime, anywhere. HYDRATION TRACKING SOLUTIONS In a variety of markets – from health care to sports, military to mining – health and safety are vital to employee wellbeing and productivity. MX3’s emerging technology in health care provides point-of-care, immediate diagnostic solutions to one of the key markers of health and safety: hydration status. MX3 Diagnostics’ revolutionary products offer the key to tracking and understanding hydration, offering point-of-care testing solutions to many common employee, workplace, and performance-related health concerns. https://linktr.ee/mx3diagnostics
11 to 50 staff
Optalert
Optalert developed the world’s leading algorithm to quantify the deterioration in cognitive brain function due to drowsiness and created the Johns Drowsiness Scale (JDS) which remains the only scientifically proven, objective measurement of drowsiness. The JDS is used worldwide in research for accurately quantifying drowsiness levels, and in Optalert’s early-warning drowsiness detection systems to protect thousands of lives and valuable company assets across multiple industries. Our clients include BHP Billiton, Vale and NASA. Our research partners include the Harvard Medical School, Monash University, and the University of Queensland. Optalert is a Medical Technology company pioneering the use of Blepharometry (the measurement of blinks) to measure drowsiness. Optalert discovered a key biomarker for drowsiness, the connection between brain function and eyelid movement. Optalert is now turning its extensive expertise in Blepharometry and Artificial Intelligence to identify the biomarkers for other degradations to neurological brain function in conditions such as Epilepsy (due to onset of seizures), ADHD, Parkinson’s, Alzheimer’s, TBI, concussion and motor neuron disease.
11 to 50 staff
Pacific Bio
At Pacific Bio, we are pioneering a world-first macroalgal circular economy that delivers scalable, cost-advantaged solutions across water, energy, agriculture, and industry. Our RegenAqua platform is a breakthrough in nature-based wastewater treatment—cleaning water while producing reliable algae biomass. That biomass fuels our entire ecosystem: PlantJuice & Bio Granules – natural biostimulants and soil enhancers helping farmers boost yields sustainably. Pacific Bio Energy – transforming algae into next-generation biofuels, including biocrude, bioethanol, and biomethane, unlocking pathways to SAF and renewable energy at scale. Data Centre Solutions – addressing the water-energy nexus by providing innovative cooling and sustainability pathways for global digital infrastructure. From wastewater to energy and agriculture, our integrated model captures value at every stage—turning environmental challenges into commercial opportunities while delivering measurable impact for people and planet. We are proud to partner with industry, utilities, governments, and research leaders to scale a truly circular solution—cleaner water, sustainable energy, healthier soils, and stronger communities.
11 to 50 staff
Vfv Pty Ltd
VFV is a manufacturer and distributor of fluid handling and process control products and systems for a wide range of Industrial, Life Science and High Purity applications. We supply engineering support, product selection advice, and application specific product training to help customers create and implement fit-for-purpose solutions, every time. We represent market-leading manufacturers, offering comprehensive solutions for hundreds of industries whom depend on gas or fluid systems to power their businesses. VFV is a creative and dedicated team of engineers, designers and industry specialists who work alongside customers right from the design phase to provide fast, accurate and proven solutions.
11 to 50 staff
Apac Scientific Pty Ltd
APAC Scientific offers high quality product solutions to scientists and medical professionals. Based in Australia, we combine expert knowledge of global brands with exceptional local service. We collaborate with innovative medical, clinical and scientific businesses to widen distribution and increase sales in the Asia Pacific region. Together with our partners, we implement comprehensive sales, marketing and support strategies that provide beneficial outcomes for our customers. Our goal is to represent the best quality products that meet the research and educational needs of our customers, and in turn align with our customers’ goals by providing informed advice and technical support at a local level.
1 to 10 staff
Etiscope
The award winning team of work safety professionals at JointAction Group are proud to introduce Etiscope. Etiscope provides you with the fastest and most accurate WMSD risk analysis technology on the market. Etiscope is backed by a team of ergonomists, researchers, medical, work health & safety, data scientists and technical experts committed to assisting businesses proactively reduce MSD injuries in the workplace.
1 to 10 staff
Fungi Solutions
Fungi Solutions was created to transform waste into valuable resources and bespoke mycelium products. We are committed to growing a sustainable and circular future for Australian manufacturing that celebrates our rich natural resources and agricultural producers. We create beautiful natural alternatives to polystyrene and leather that are lightweight, durable, insulating and 100% home compostable.
1 to 10 staff
Gelomics
Gelomics revolutionises drug development by providing a more predictive, ethical alternative to traditional cell and animal models. We enable scientists to grow functional human microtissues using our AI-powered technology, which significantly improves the accuracy of drug response predictions. This innovation reduces costs, shortens development timelines, and decreases reliance on animal testing, offering a more efficient and humane approach to pharmaceutical research. Our mission is to accelerate therapeutic breakthroughs, ensuring faster, safer, and more humane medical advancements.
11 to 50 staff
Glytherix Ltd
GlyTherix Ltd, is a targeted radiotherapy company with a clinical stage antibody product, Miltuximab®, showing an excellent safety profile in high unmet need cancers. Miltuximab® specifically targets GPC-1, a protein found on solid tumours such as prostate, bladder, pancreatic, glioblastoma, oesophageal and ovarian cancers, and is not present in healthy tissue. There is a large addressable market in the USA and Europe of US$21.7 billion per annum. The company has a strong proprietary and intellectual property position covering the Miltuximab® antibody, epitope and the antigen. This provides robust and long-term protection for the commercialization of important new treatments to people with little hope. Miltuximab® precisely delivers targeted radiation to cancer cells. The company chelates a low energy 89Zirconium isotope to the antibody for diagnostic imaging. Image positive patients can then receive a dose of Miltuximab® that is chelated to the high energy isotope 177Lutetium resulting in a cell destroying dose directly at the site of the cancer. GlyTherix also has a pre-clinical program underway investigating the use of alpha particles, ie 225Actinium and 212Lead. GlyTherix has completed a ‘First-in-Human’ trial of 12 patients using Miltuximab® with no drug-related adverse. events. Miltuximab® will be used in both the Phase Ib and US Phase 2 trials as an antibody theranostic. The company has entered an exclusive manufacturing, supply & distribution agreements with reliable isotope suppliers ANSTO and Cyclowest Holdings, both highly regarded nuclear medicine companies in Australia. Agreements with US based CDMOs and isotope suppliers for our planned US trials are also in place. GlyTherix has a strong management and research team and a highly experienced clinical advisory panel who have been intimately involved in commercialisation of targeted radiotherapies that are marketed in the US and elsewhere.
1 to 10 staff
Proagni
About ProAgni ProAgni is an agricultural bioscience company dedicated to transforming animal agriculture through innovative and sustainable solutions. With a focus on reducing the environmental impact of food production, we develop and commercialize groundbreaking animal nutrition products that enhance farm profitability while addressing global challenges such as antibiotic use and enteric methane emissions. Our Mission At ProAgni, our mission is to drive sustainability in agriculture by discovering and delivering products that not only improve the performance and health of livestock but also significantly reduce methane emissions and antibiotic use. We believe in creating solutions that benefit both farmers and the planet. Our Innovations Our flagship product line, ProTect, offers feed supplements for cattle and sheep that- Increase animal performance, boosting farm profitability - Decrease methane emissions, contributing to climate change mitigation - Contain no antibiotics, helping combat antimicrobial resistance
1 to 10 staff
Canthera Discovery Canthera Discovery Ltd
Canthera Discovery is dedicated to Finding Cures for Cancer. We are a small molecule, oncology focused, drug discovery organisation that partners with leading Australian research institutes, universities and biotech companies. We translate Australia’s cancer research into the next generation of gentler and more effective therapies for patients by bridging the gap between basic research and commercial outcomes. We were established in 2007 under the Australian government’s Cooperative Research Centre (CRC) initiative. Since our inception, we have licensed four preclinical candidates, and delivered two of the largest preclinical deals in Australia. These deals have delivered $40 million in pharmaceutical revenue to the Australian economy with the potential to grow in excess of $600 million long-term. We have executed three collaborative cancer research deals with international pharmaceutical companies such as Pfizer, MSD and Amplia.
51 to 200 staff
Effica Biolabs
A brief overview of Effica Biolabs- We test the therapeutic potential of drugs and devices for a range of immune-related diseases to help establish the smoothest path to clinic- We work with our clients to develop and implement testing approaches that integrate animal disease models and human tissue assays. We can apply our animal models and standardised assays for human peripheral blood analysis, pharmacodynamics and pharmacokinetics- We are a proud service offering of St Vincent's Institute of Medical Research in Fitzroy (a suburb of Melbourne) Australia- To find out more about what we can bring to your project, please contact Professor Helen Thomas or Dr Tom Brodnicki by email efficabiolabs@svi.edu.au or phone +61 3 9231 2480. We look forward to hearing from you.
11 to 50 staff
